A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Stephen A HarrisonPierre BedossaCynthia D GuyJörn Markus SchattenbergRohit LoombaRebecca TaubDominic LabriolaSam E MoussaGuy W NeffMary E RinellaQuentin M AnsteeManal F AbdelmalekZobair M YounossiSeth J BaumSven M FrancqueMichael R CharltonPhilip Noel NewsomeNicolas LanthierIngolf SchiefkeAlessandra MangiaJuan M PericàsRashmee PatilArun J SanyalMazen NoureddinMeena B BansalNaim AlkhouriLaurent CasteraMadhavi RudrarajuVlad Ratziunull nullPublished in: The New England journal of medicine (2024)
Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).